SignalXSignalX

Gilead Sciences (GILD) 8-K Current Report: February 23, 2026

Filed: February 23, 2026
Health Care
Biological Products, (No Diagnostic Substances)
Gilead Sciences Overview

Gilead Sciences (GILD) 8-K current report filed with SEC EDGAR on February 23, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
2 items

  • Item 7.01: Regulation FD Disclosure
  • Item 1.01: Entry into a Material Definitive Agreement

Gilead Sciences 8-K Feb 23, 2026 Event Analysis

Item 1.01 · Entry into a Material Definitive Agreement

  • • Gilead acquiring Arcellx at $115.00/share cash + $5.00 CVR per share, implying up to $120.00 total consideration per Arcellx share
  • • CVR milestone: $5.00 payment contingent on anito-cel cumulative global sales exceeding $6B by December 31, 2029 — high bar, meaningful execution risk
  • • Tender offer structure via wholly owned sub Ravens Sub, Inc.; requires >50% share tender plus HSR antitrust clearance to close
  • • Breakup fee: $260M payable by Arcellx to Gilead if Company walks to accept a Superior Offer — ~2.2% of deal at $115/share base
  • • Insider support locked up: directors, executives, NEA, and SR One — collectively ~10.3% of shares — already committed to tender

Item 7.01 · Regulation FD Disclosure

  • • Gilead pursuing full acquisition of Arcellx via tender offer — deal not yet commenced, SEC filings pending
  • • Key asset: anito-cel (CAR-T therapy), with active BLA under FDA review and a PDUFA date already set
  • • Transaction expected to be accretive to Gilead following FDA approval; CVR included, tied to milestone achievement
  • • Closing risks include regulatory approval, Arcellx shareholder tender participation, and potential competing bids
  • • Arcellx stockholders urged to await formal Schedule TO/14D-9 filings before making any tender decision

Get deeper insights on Gilead Sciences

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.